This is a Validated Antibody Database (VAD) review about human vaccinia related kinase 1, based on 5 published articles (read how Labome selects the articles), using vaccinia related kinase 1 antibody in all methods. It is aimed to help Labome visitors find the most suited vaccinia related kinase 1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
vaccinia related kinase 1 synonym: PCH1; PCH1A
Santa Cruz Biotechnology
mouse monoclonal (E-3) |
| Santa Cruz Biotechnology vaccinia related kinase 1 antibody (Santa cruz, Sc390809) was used in western blot on human samples at 1:500 (fig 6a). J Virol (2017) ncbi |
mouse monoclonal (1F6) |
| In order to use size exclusion chromatography-microsphere-based affinity proteomics to study clinical samples obtained from pediatric acute leukemia patients, Santa Cruz Biotechnology vaccinia related kinase 1 antibody (SCBT, 1F6) was used in other on human samples (fig st1). Mol Cell Proteomics (2016) ncbi |
mouse monoclonal (1F6) |
| Santa Cruz Biotechnology vaccinia related kinase 1 antibody (Santa Cruz, clone 1F6) was used in western blot on human samples at 1:500. Cancer Cell (2014) ncbi |
Abcam
mouse monoclonal (5D1) |
| Abcam vaccinia related kinase 1 antibody (Abcam, ab171933) was used in immunohistochemistry - paraffin section on human samples at 1:500 (fig 2d). Front Pharmacol (2022) ncbi |
Cell Signaling Technology
mouse monoclonal (1F6) |
| In order to learn about vulnerability in Ewing sarcoma by splicing of the EWS-FLI1 fusion transcript discovered thrugh functional genomic screening, Cell Signaling Technology vaccinia related kinase 1 antibody (Cell signaling, 3307) was used in western blot on human samples (fig 4b). Cell Rep (2016) ncbi |
Articles Reviewed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments